Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jul 1, 2026
Reporting period
Not applicable
Filed with the SEC
Jul 7, 2026
DirectorIndirect holdingOther
Context
Classification
other
Code J — not an open-market trade
Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001213900-26-075538
Filed / recorded
Jul 7, 2026, 12:34 AM UTC
Added to OQRO
Oct 8, 2026, 12:20 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
BridgeBio Oncology Therapeutics, Inc.
Issuer CIK
1869105
Ticker
BBOT
Reporting person
Bihua Chen
Relationship
Director, 10% owner
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jul 1, 2026
Transaction code
J
Shares / units
1,704,862
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
5,010,332
Ownership form
Indirect — Via Fund V
Amendment
No
Footnotes from the filing
Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration.
CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.